Literature DB >> 33740185

Cytokine signaling pathway in cystic fibrosis: expression of SOCS and STATs genes in different clinical phenotypes of the disease.

Swati Sagwal1, Rajendra Prasad2, Jyotdeep Kaur3, Meenu Singh4.   

Abstract

This was an observational cross-sectional study which was done to assess the expression profile of STATs and SOCS genes in cystic fibrosis. The mRNA was isolated from peripheral blood mononuclear cells of CF patients in exacerbation, colonization and post exacerbation phases of the disease. The relative gene expression level for SOCS 1, -3, -5 and STAT 1, -3,-4,-6 genes was quantified by Real-time PCR. The levels of IL-6 were also measured in the serum by ELISA. The expression of the Th1 pathway associated genes (SOCS1, SOCS5, STAT4 and STAT1) was downregulated while the expression of Th2/Th17 pathway genes (SOCS3, STAT3, STAT6) was upregulated in both exacerbation and colonization phases as compared to healthy controls. The serum levels of IL-6 were also elevated in both the disease groups. After antibiotic treatment, the expression of SOCS5 and STAT4 was increased while the expression of rest of the genes showed downregulation which shows a shift in immune response from Th2/Th17 to Th1. Our results suggest that infection alters the cytokine signaling pathway through modulation of STATs and SOCS genes which is not able to regulate the overstimulation of cytokine signaling further leading to chronic inflammation in CF.

Entities:  

Keywords:  Cystic fibrosis; Cytokine signaling; Inflammation; Th1/Th2 cytokines

Mesh:

Substances:

Year:  2021        PMID: 33740185     DOI: 10.1007/s11010-021-04051-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  27 in total

Review 1.  SOCS: role in inflammation, allergy and homeostasis.

Authors:  Joanne Elliott; James A Johnston
Journal:  Trends Immunol       Date:  2004-08       Impact factor: 16.687

2.  Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials.

Authors:  D Bilton; G Canny; S Conway; S Dumcius; L Hjelte; M Proesmans; B Tümmler; V Vavrova; K De Boeck
Journal:  J Cyst Fibros       Date:  2011-06       Impact factor: 5.482

Review 3.  Immunomodulatory Cell Therapy to Target Cystic Fibrosis Inflammation.

Authors:  Oula Khoury; Christopher Barrios; Victor Ortega; Anthony Atala; Sean V Murphy
Journal:  Am J Respir Cell Mol Biol       Date:  2018-01       Impact factor: 6.914

4.  Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients.

Authors:  M S Muhlebach; P W Stewart; M W Leigh; T L Noah
Journal:  Am J Respir Crit Care Med       Date:  1999-07       Impact factor: 21.405

Review 5.  Mechanisms and markers of airway inflammation in cystic fibrosis.

Authors:  V De Rose
Journal:  Eur Respir J       Date:  2002-02       Impact factor: 16.671

Review 6.  Pathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis: current understanding and future directions.

Authors:  Rekha R Rapaka; Jay K Kolls
Journal:  Med Mycol       Date:  2008-07-29       Impact factor: 4.076

Review 7.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

8.  Inflammatory cytokines in cystic fibrosis lungs.

Authors:  T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

Review 9.  Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function.

Authors:  Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2009-10-30       Impact factor: 16.687

Review 10.  Origins of cystic fibrosis lung disease.

Authors:  David A Stoltz; David K Meyerholz; Michael J Welsh
Journal:  N Engl J Med       Date:  2015-01-22       Impact factor: 91.245

View more
  2 in total

Review 1.  Mucosal Immunity in Cystic Fibrosis.

Authors:  Christine M Bojanowski; Shiping Lu; Jay K Kolls
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.426

Review 2.  Role of inflammation and oxidative stress in tissue damage associated with cystic fibrosis: CAPE as a future therapeutic strategy.

Authors:  Victor Emanuel Miranda Soares; Thiago Inácio Teixeira do Carmo; Fernanda Dos Anjos; Jonatha Wruck; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini; Débora Tavares de Resende E Silva
Journal:  Mol Cell Biochem       Date:  2021-09-16       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.